RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a 1-for-8 reverse stock split effective at 11:59 pm ET on June 16, 2025. Post-split, the company's common stock will trade under the symbol "RAPT" with a new CUSIP number starting June 17, 2025. This adjustment reduces the outstanding shares from approximately 132.3 million to 16.5 million, without altering the total number of authorized shares. The reverse split affects all shareholders equally and maintains their relative equity stakes, with adjustments made for fractional shares through cash payments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.